Opthea Limited Sponsored ADR (OPT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opthea Limited announces strategic executive team changes, including the appointment of Daniel Geffken as interim CFO and Mike Campbell as CCO, in preparation for the Phase 3 topline data readouts of their retina treatment in 2025. The company has also strengthened its leadership with new hires in Biometrics, Clinical Operations, and Market Access, aiming to bolster their expertise in retina diseases and enhance their commercial capabilities. These changes come as Opthea progresses towards the potential launch of sozinibercept for wet age-related macular degeneration.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.